Methotrexate in pediatric plaque-type psoriasis: Long-term daily clinical practice results from the Child-CAPTURE registry
Authors:
- 20 January 2015
- journal article
- research article
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 26 (5) , 406-412
Abstract
Evidence on effectiveness and safety of methotrexate (MTX) in pediatric psoriasis is scarce. To study the effectiveness and safety of MTX in pediatric plaque-type psoriasis and its influence on quality of life (Qol) in daily clinical practice. Subset analysis of prospectively collected data extracted from the Child-CAPTURE registry, a single center, longitudinal, long-term, observational daily practice cohort of pediatric psoriasis patients. A maximum dose between 0.14 and 0.63 mg/kg once weekly was prescribed in 25 children. Primary endpoints were percentages of patients with ≥ 75% improvement in the Psoriasis Area and Severity Index (PASI) at week 12 and 24. PASI75 was achieved in 4.3% and 33.3% of patients at week 12 and 24, whereas 40% and 28.6% reached PASI 75 at week 36 and 48. Median PASI and body surface area decreased from 10.0 (range 3.8-42.4) and 11.0 (range 3.5-72.0) at baseline to 4.3 (range 0-19.8) and 2.6 (range 0.0-39.6) at week 24, respectively. Physician Global Assessment improved significantly from 3.0 to 1.2 at week 24. A significant decrease in Children's Dermatology Life Quality Index from 9.0 to 3.8 at week 24 was found. Most reported adverse events were severe nausea (n = 5), infections requiring antibiotics (n = 5) and tiredness (n = 4). MTX shows a positive effect on PASI scores, improves Qol and has a reasonable safety profile.Keywords
This publication has 31 references indexed in Scilit:
- Systemic methotrexate therapy for psoriasis: past, present and futureClinical and Experimental Dermatology, 2013
- The influence of treatments in daily clinical practice on the Children’s Dermatology Life Quality Index in juvenile psoriasis: a longitudinal study from the Child-CAPTURE patient registryBritish Journal of Dermatology, 2012
- A cross-sectional study using the Children’s Dermatology Life Quality Index (CDLQI) in childhood psoriasis: negative effect on quality of life and moderate correlation of CDLQI with severity scoresBritish Journal of Dermatology, 2010
- The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical useBritish Journal of Dermatology, 2010
- Efficacy and safety of treatments for childhood psoriasis: A systematic literature reviewJournal of the American Academy of Dermatology, 2010
- What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literatureJournal of the European Academy of Dermatology and Venereology, 2010
- Methotrexate treatment in 13 children with severe plaque psoriasisClinical and Experimental Dermatology, 2009
- Systemic Methotrexate Treatment in Childhood Psoriasis: Further Experience in 24 Children from IndiaPediatric Dermatology, 2008
- A Comparative Study of Pediatric Onset Psoriasis with Adult Onset PsoriasisPediatric Dermatology, 2000
- Methotrexate in Childhood PsoriasisPediatric Dermatology, 1994